These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6164559)

  • 1. Selective enhancement of 5-fluorouridine uptake and action in rat hepatomas in vivo following pretreatment with D-galactosamine and 6-azauridine or N-(phosphonacetyl)-L-aspartate.
    Anukarahanonta T; Holstege A; Keppler DO
    Eur J Cancer (1965); 1980 Sep; 16(9):1171-80. PubMed ID: 6164559
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
    Karle JM; Anderson LW; Erlichman C; Cysyk RL
    Cancer Res; 1980 Aug; 40(8 Pt 1):2938-40. PubMed ID: 7388844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of N-phosphonacetyl-L-aspartate and D-glucosamine on the incorporation of 5-fluorouridine into normal tissues and an adenocarcinoma in the rat.
    Erichsen C; Christensson PI; Jakobsson B; Eriksson G; Yngner T; Jönsson PE; Stenram U
    Anticancer Res; 1987; 7(1):77-80. PubMed ID: 3566186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of psoriasis to N-phosphonacetyl-L-aspartate.
    Earhart RH; DeConti RC; Rubin J; Ohnuma T
    Lancet; 1981 Jun; 1(8232):1257-8. PubMed ID: 6112581
    [No Abstract]   [Full Text] [Related]  

  • 5. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
    Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B
    Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice.
    Karle JM; Anderson LW; Dietrick DD; Cysyk RL
    Cancer Res; 1981 Dec; 41(12 Pt 1):4952-5. PubMed ID: 6171344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.
    Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Young CW
    Cancer Res; 1983 Oct; 43(10):4653-61. PubMed ID: 6603903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
    Carroll DS; Gralla RJ; Kemeny NE
    Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
    Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
    Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
    Johnson RK; Swyryd EA; Stark GR
    Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
    [No Abstract]   [Full Text] [Related]  

  • 11. Depletion of blood plasma cytidine due to increased hepatocellular salvage in D-galactosamine-treated rats.
    Holstege A; Manglitz D; Gerok W
    Eur J Biochem; 1984 Jun; 141(2):339-44. PubMed ID: 6734601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased formation of nucleotide derivatives of 5-fluorouridine in hepatoma cells treated with inhibitors of pyrimidine synthesis and D-galactosamine.
    Holstege A; Herrmann B; Keppler DO
    FEBS Lett; 1978 Nov; 95(2):361-5. PubMed ID: 720629
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition by N-(phosphonacetyl)-L-aspartate of Ehrlich ascites tumour growth and glucose transport.
    Leung SW; Fung KP; Choy YM; Lee CY
    Cancer Lett; 1984 Jun; 23(2):183-8. PubMed ID: 6744243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
    Grant S; Rauscher F; Jakubowski A; Cadman E
    Cancer Res; 1981 Feb; 41(2):410-8. PubMed ID: 6160908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
    Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
    Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in human mammary carcinoma.
    Ardalan B; Glazer RI; Kensler TW; Jayaram HN; Van Pham T; Macdonald JS; Cooney DA
    Biochem Pharmacol; 1981 Aug; 30(15):2045-9. PubMed ID: 7295324
    [No Abstract]   [Full Text] [Related]  

  • 17. Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
    Martin DS; Stolfi RL; Sawyer RC; Young CW
    Cancer Treat Rep; 1985 Apr; 69(4):421-3. PubMed ID: 3888389
    [No Abstract]   [Full Text] [Related]  

  • 18. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
    Moyer JD; Handschumacher RE
    Cancer Res; 1979 Aug; 39(8):3089-94. PubMed ID: 455293
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of psoriasis with N-phosphonacetyl-L-aspartate.
    Doyle JA; Perry HO; Rubin J; Moertel CG
    J Am Acad Dermatol; 1984 Jan; 10(1):21-4. PubMed ID: 6229552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of antimetabolite action by uridylate trapping.
    Keppler D; Holstege A; Weckbecker G; Fauler J; Gasser T
    Adv Enzyme Regul; 1985; 24():417-27. PubMed ID: 3835824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.